Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : T.ITE: iTech Capital (TSE) -- Ignore unavailable to you. Want to Upgrade?

To: Rob Davis who wrote (3151)	12/16/1999 11:01:00 AM
From: Condor	Read Replies (2) \| Respond to of 5053

Rob, I think you're right and I believe the impact will be huge on the IPO values by far offsetting any dilutive disadvantage. I believe this will pay off for JDX BIGtime. C

To: Rob Davis who wrote (3151)	12/16/1999 1:25:00 PM
From: keith massey	Read Replies (1) \| Respond to of 5053

Rob Nobody can argue that this latest round will substantially increase the value of Medsite. The good news is that the $19 and $36 million financing were done after JDX's which means they likely paid higher than $5U.S a share and Medsite.com had to issued less than 10 million shares for all of this money. From my count Medsite.com we will have around 35-40 million shares out when they IPO which is normal for this type of issue. With The Goldman Sachs, Morgan Stanley Dean Witter Venture Partners, and Chase Capital all on board now we are laughing on getting promo for this IPO. And you probably already know that JDX is the only public company holding shares of Medsite.com. This could be fun come IPO time <ggg> Best Regards KEITH